key: cord-0865808-8mlekb2j authors: O’Horo, John Charles; Cerhan, James R.; Cahn, Elliot J.; Bauer, Philippe R.; Temesgen, Zelalem; Ebbert, Jon; Abril, Andy; Abu Saleh, Omar M.; Assi, Mariam; Berbari, Elie F.; Bierle, Dennis M.; Bosch, Wendelyn; Burger, Charles D.; Cano Cevallos, Edison J.; Clements, Casey M.; Carmona Porquera, Eva M.; Castillo Almeida, Natalia E.; Challener, Douglas W.; Chesdachai, Supavit; Comba, Isin Y.; Corsini Campioli, Cristina G.; Crane, Sarah J.; Dababneh, Ala S.; Enzler, Mark J.; Fadel, Hind J.; Ganesh, Ravindra; De Moraes, Alice Gallo; Go, John R.; Gordon, Joel E.; Gurram, Pooja R.; Guru, Pramod K.; Halverson, Erika L.; Harrison, Michael F.; Heaton, Heather A.; Hurt, Ryan; Kasten, Mary J.; Lee, Augustine S.; Levy, Emily R.; Libertin, Claudia R.; Mallea, Jorge M.; Marshall, William F.; Matcha, Gautam; Meehan, Anne M.; Franco, Pablo Moreno; Morice, William G.; O’Brien, Jennifer J.; Oeckler, Richard; Ommen, Steve; Oravec, Caitlin P.; Orenstein, Robert; Ough, Natalie J.; Palraj, Raj; Patel, Bhavesh M.; Pureza, Vincent S.; Pickering, Brian; Phelan, David M.; Razonable, Raymund R.; Rizza, Stacey; Sampathkumar, Priya; Sanghavi, Devang K.; Sen, Ayan; Siegel, Jason L.; Singbartl, Kai; Shah, Aditya S.; Shweta, F.N.U.; Speicher, Leigh L.; Suh, Gina; Tabaja, Hussam; Tande, Aaron; Ting, Henry H.; Tontz, Russell C.; Vaillant, James J.; Vergidis, Paschalis; Warsame, Mohamed Y.; Yetmar, Zachary A.; Zomok, Catherine D.; Williams, Amy W.; Badley, Andrew D. title: Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research date: 2020-12-26 journal: Mayo Clin Proc DOI: 10.1016/j.mayocp.2020.12.006 sha: b48add1d6d1b17eb3fb8b4030a829d9c80d88b50 doc_id: 865808 cord_uid: 8mlekb2j Objective To report the Mayo Clinic experience with COVID-19 related to patient outcomes. Methods We conducted a retrospective chart review of patients diagnosed with COVID-19 between March 1, 2020 and July 31, 2020 at any of the Mayo Clinic sites. We abstracted pertinent comorbidities such as age, gender, body mass index, Charlson Comorbidity Index (CCI) variables, and treatments received. Factors associated with hospitalization and mortality were assessed in univariate and multivariate models. Results A total of 7,891 patients with confirmed COVID-19 with research authorization on file received care across the Mayo Clinic during the study period. Of these, 7217 patients were adults ≥ 18 years old which were analyzed further. 897 (11.3%) patients required hospitalization, and 354 (4.5%) patients received care in the Intensive Care Unit (ICU). All hospitalized patients were reviewed by a COVID-19 Treatment Review Panel, and 77.5% of inpatients received a COVID-19 directed therapy. Overall mortality was 1.1%, with 7.1% mortality in hospitalized patients and 11.9% in patients requiring ICU care. Conclusion Mayo Clinic outcomes of COVID-19 patients in the ICU, hospital and community compare favorably to those reported nationally. This likely reflects the impact of interprofessional multidisciplinary team evaluation, effective leveraging of clinical trials and available treatments, deployment of remote monitoring tools, and maintenance of adequate operating capacity to not require surge adjustments. These best practices can help guide other health care systems with the continuing response to the COVID-19 pandemic. By the time the World Health Organization declared coronavirus disease 2019 to be a pandemic, the illness was already an unprecedented challenge for healthcare systems. Initial reports from Wuhan, China, suggested that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was highly transmissible and posed significant challenges related to prevention, containment, and treatment. Subsequent experience in Italy, Spain, Seattle and New York City confirmed these challenges, and hospital systems throughout the world had to brace for the impact of COVID-19. The Mayo Clinic is comprised of sites in Phoenix/Scottsdale, Arizona, Jacksonville, Florida, Rochester, Minnesota and additional hospitals in Minnesota and Wisconsin. The Mayo Clinic enterprise has 2680 licensed hospital beds and 392 regular ICU beds spanning 20 campuses in 4 states. The clinic served 1.2 million patients last year. Early during the pandemic and anticipating significant changes to the practice, Mayo Clinic leadership activated the Hospital Incident Command System and assembled several teams and task forces charged with developing processes and protocols to address the multifaceted pandemic response, including anticipated case surges. 1 A multilayered integrated approach was taken to manage the COVID-19 pandemic at Mayo Clinic. Interprofessional workgroups were developed across multiple impacted specialties to appraise the emerging literature on topics like testing strategies 2 and thromboprophylaxis. 3 As necessary, providers with specific expertise in organ-specific complications, such as nephrology, hematology, neurology, among others, were invited to be part of the team and to provide input as treatment algorithms were developed and matured. These best practices were compiled and shared with the Mayo Clinic staff in real time through the AskMayoExpert platform, a clinical knowledge resource that serves the Mayo Clinic practice. The Mayo Clinic COVID-19 Data Governance Task force set up monitoring tools to inform the practice on resource utilization and forecast demand related to COVID-19. This allowed safe management of anticipated COVID-19 cases and ongoing medical practice needs. A COVID-19 research task force was created to select and execute treatment trials, coordinate biospecimen collection, create databases and advance augmented intelligence-facilitated analytics, prioritize pre-clinical bio-discovery science in immunology, virology, vaccine development and respond to the needs of minority populations disproportionately affected by Recognizing that treatments and treatment guidelines for COVID-19 would change over time, different processes were employed to create a consistent system in which patients were screened for possible trial participation in the outpatient and inpatient settings. Mayo Clinic saw its first COVID-19 case in March 2020, and all regions were actively engaged in caring for patients with COVID-19 by the end of that month. Patients with COVID-19 admitted to our hospitals were reviewed by Treatment Review panels at each site. This multidisciplinary group provided recommendations as to which clinical trials and emerging therapies would be most beneficial for patients with COVID-19. The panels convened twice per day, and more frequently as needed. Every patient was assessed on hospital admission and consensus-driven recommendations were based upon available treatment options through clinical trials, Emergency Use Authorization (EUA) Expanded Access Programs (EAP) or off label use. Trials and programs had varying start times across Mayo Clinic, and the panels reviewed patients based on local availability and protocols for agents like Remdesivir and convalescent plasma. The panel directed antiviral and immunomodulatory treatments, as well as management of complications. Recommendations were provided to primary treatment teams and the patient / patient's legally authorized representative in a shared decision making process. 4 The treatment review panel also did weekly webcasts available to all providers to give up to date education as data emerged. Mayo Clinic also developed a "COVID-19 Frontline Care Team" or COVID virtual clinic for outpatient care in conjunction with a nurse phone line which patients were telephonically triaged based on disease severity for testing at "drive-through" facilities or the Emergency Department. 5 All SARS CoV-2 positive tests from outpatients at our institution were routed to this centralized team of physicians and nurses with the goal of contacting them in 35 kg/m 2 ) (OR 2.86, 95% CI 2.21-3.70). Most patients were never (60.8%) or former (26.8%) smokers, and smoking was not associated with odds of hospitalization, though this variable was frequently missing in outpatients. In a multivariate model, increasing age, obesity, race/ethnicity, and most of the individual components of the CCI were significantly associated with increased odds of hospitalization. The month of diagnosis was also a significant covariate, as odds of admission was lower in May, June, and July relative to March and April. Of the 897 requiring hospital admission, 354 (39.5%) required ICU admission. Risk of ICU admission was associated with age, with peak risk in ages 55-74 years (OR 2.27, 95% CI 1.33-3.57). Although males made up most ICU admissions (55.6%), this was not a statistically significant risk factor. Black race was associated with higher ICU admission (unadjusted OR 1.93, CI 1.23-3.04), and Asian race was associated with the highest risk of ICU admission in the multivariate model (2.84 95% CI 1.35-6.13). A language other than English as a primary language was present in 11.9% of patients overall, and 13.4% of hospital admissions. Strikingly, 150 patients admitted to the ICU (42.4%) reported a language other than English as their primary language. Elevated AST but not ALT, an elevated creatinine and neutrophil-lymphocyte ratio were associated with a higher risk of ICU admission. Other characteristics of the CBC, such as absolute counts of lymphocytes, neutrophils and eosinophils were not associated with outcomes. These findings are summarized in Table 3 as well as Supplemental Tables 1 and 2 . A total of 354 patients were admitted to the ICU for care of COVID-19 across the enterprise. Median ICU length of stay (LOS) was 6.19 days (0.24-76.4). 30.5% of ICU patients were on high flow nasal cannula for a portion of their hospital stay, 23.2% required noninvasive mechanical ventilation, 29.9% required invasive mechanical ventilation, and 4.5% required extracorporeal membrane oxygenation (ECMO). Median APACHE IV score was 57 (range 9-180) and median admission SOFA score was 2 (range 0-18). Overall mortality was 11.9%, and mean ICU LOS was 9.1 days. The predicted mortality by the APACHE IV model was 13.2% and LOS averaging 5.2 days, indicating a standardized mortality ratio of 0.90. Therapeutics were almost exclusively administered to hospitalized patients. A total of 695 (77.5%) patients received a COVID-19 directed treatment, with a higher proportion of ICU patients (89.3%) receiving such treatments. A total of 370 (41.2%) patients received an antiviral, 433 (48.3%) received systemic steroids, 153 (17.1%) received an immunomodulatory monoclonal antibody, and 192 (21.4%) received convalescent plasma. Overall, 507 patients (56.5%) were enrolled in a clinical trial. Several patients received combinations of therapies; 32 (3.5%) received all of these therapies, 119 (13%) a combination of three, and 242 (24.3%) received two therapies. The most common combinations paired steroids with one of the other treatments, most commonly antivirals, and all permutations of treatment classes were administered. ARDS was present in 152 (16.9%) patients, as defined by noting this in the patient's problem list during their hospital stay. Acute kidney injury occurred in 185 (20.6%) of inpatients during their COVID-19 episode. Diagnosed thrombotic and embolic complications were also common, occurring in 127 (14.2%) patients. Respiratory culture-confirmed bacterial superinfections were recorded in 141 (5.7%) patients. Bloodstream infections were present in 29 (3.2%) patients. All complications were more common in patients admitted to the ICU (Table 4 ). For the entire cohort, outcomes by month using the NIH Ordinal Scale indicated a decrease in the worst severe outcomes (levels 1-5, hospitalizations required) through July (Figure 3 ). In this overall cohort, 94 patients died. We conducted a survival analysis among hospitalized patients, calculating 30 day mortality rates (based on Kaplan-Meier estimates) for selected patient characteristics, summarized in Table 5 overall and in Supplemental Table 1 for individual CCI elements. In the multivariable model, older age, earlier month of diagnosis, high CCI score (≥2), ever smoking, elevated creatinine, and higher NLR were all associated with lower rates of survival. A total of 7891 COVID-19 patients with confirmed COVID-19 disease received care at Mayo Clinic between March 1, 2020 and July 31, 2020. Among these patients, 897 (11.3%) required hospitalization, and 354 (4.5%) required ICU care. We observed an overall mortality rate of 1.1%, an inpatient mortality of 7.1% and an ICU mortality of 11.9%. Our observed mortality rates are lower than the national average and lower than what has been reported from various observational cohorts across the country, large clinical trials, and expanded access programs. The acuity of our patients, as indicated by APACHE IV scores, was moderately severe, but the standardized mortality ratio indicates modestly reduced mortality compared to what would be expected. As of September 4, 2020, a total of 6132074 cases of COVID-19 have been reported in the United States, with 186,173 deaths (3%). 18 Rates of mortality reported in hospitalized patients vary widely but have consistently been higher than what was observed here. In a cohort study that included 11,210 adult patients with confirmed COVID-19 who presented to 92 hospitals of a healthcare organization located in 12 states, 7139 (63%) required hospitalization; among these hospitalized patients, 2866 (40%) required ICU care. An overall in-hospital mortality of 20.3% and a mortality rate of 34.7% among those with an ICU stay were reported. 19 A prospective cohort study from a healthcare organization in New York City reported 51.9% of patients required hospitalization, 36.1% required ICU, and 24.3% overall mortality. 20 Other New York based studies indicated 21% mortality 21 and 22% mortality 22 among hospitalized patients. Connecticut reported 13.5% mortality in a hospital-based study. 23 Nationally, the multicenter, open-label expanded access program of convalescent plasma in hospitalized adults with COVID-19 involved 35,322 patients receiving care at 1,809 sites across the United States. In this study, 30-day mortality of hospitalized patients was 24.5% during the study period. In the double-blind, randomized, placebo-controlled trial of intravenous Remdesivir in adults hospitalized with COVID-19, the following mortality rates at day 14 were reported: overall 86/1059 (8%); placebo arm 54/521 (10%); Remdesivir arm 32/538 (6%). 8 A study of mortality across countries found the age demographics accounted for the majority of the observed variation in fatality rates. In this study, fatalities ranged from 0.002% in those <34 years old and 28.3% in those 85 years and older; 24 our observed mortality was lower in each age bracket. The observed decline in mortality over time has been previously observed. One possible explanation for this is that it reflects selection bias; early in the outbreak, testing was prioritized to those with specific symptoms, thereby selecting for those with more severe illness. Later in the epidemic, testing included asymptomatic individuals, who would be expected to have less severe illness. Second, as the Mayo sites were not involved in the initial wave of infections within North America, we had the advantage of learning from the clinical experience and insights of our colleagues worldwide. Indeed, most of the comparators cited above were in the east coast and New York in particular, which bore the brunt of the first wave with disruptions to every aspect of local health care. Another factor may have been our outpatient COVID-19 management teams and remote monitoring capabilities, allowing complications, and deterioration to be detected earlier and interventions put in place in a more timely manner. The high proportion of our patients able to participate in these programs was likely a contributor to our outcomes. A possible contributor to decreased mortality over time was the attenuating effects of masks and social distancing, reducing inoculum of exposure and potentially reducing the severity of illness. 25 Also, differential mortality among strains of SARS-CoV-2 has been postulated, and the impact of different sub-strains on population outcomes and shifts in strains over time and space are not yet understood. 26 Finally, best practices in critical care, and excellent multidisciplinary ICU care were maintained according to Mayo's model of care. In the early epidemic, early intubation was a more common practice based on the assumption that patients would always decline rapidly 27 and to limit exposure of health care workers to aerosol generated procedures. 28 However, we learned very quickly that, although some patients deteriorated rapidly and required intubation, most of them would be placed early on high flow nasal cannula, less often on noninvasive ventilation, encouraged to self-prone and ultimately would not require intubation, though the effect of individual aspects of this bundled approach cannot be analyzed here, and some elements of it have recently been subject to controversy. 29 Among those intubated, adherence with best supportive care was encouraged early. 30 Special emphasis was made on lung protective strategy, early prone positioning, conservative fluid strategy, judicious use of sedative and neuromuscular blocking agents and management of the hypercoagulable state 3 as well as adherence to the modified ABCDEF bundle. 31 Although ECMO use was infrequent, going to ECMO early once it was determined to be indicated may have contributed as well. Critical to our outcomes was the ability to confirm the diagnosis of COVID-19 quickly following sample collection within 12 to 24 hours. Therefore, patients were evaluated early during their COVID-19 disease. Patients not requiring hospitalization were closely monitored from home by a structured telemedicine system. Each and every hospitalized patient was reviewed by the multidisciplinary Treatment Review Panel that, in collaboration with the primary team, made recommendations on the best supportive care based on evidence as they became available and progressed with time 8, 32 , and offered COVID-19 directed therapies, clinical trial options, as well as general infectious disease consultation. These therapies were communicated to the patient by an Infectious Disease provider. This method, while requiring significant resources, ensured high-quality communication with the primary teams, and the application of latest evidence available as reviewed by the multidisciplinary team. Trials of antiviral therapy were available early, which accounts for a large proportion of patients who received them (41% of hospitalized patients). Despite our individualized approach, with emphasis on limiting their use to those with a rapid deterioration on imaging, oxygenation or clinical appearance, or those with a propensity to do so or those who had an established indication (e.g. COPD, asthma, chronic use, pregnancy and septic shock), a fair proportion (50%) received glucocorticoids. The use of convalescent plasma was more restrained and more common in those with contraindications to remdesivir (e.g. abnormal liver function, or renal failure). In some instances, the use of antivirals was limited due to temporary lack of availability. The use of specific immunomodulatory agents (e.g. interleukin 6 inhibitors) was limited (17%). It was initially used under emergency Investigational New Drug (eIND) authorization and later mostly in randomized control trial only and rarely under an expanded access program. 33 The Treatment Review Panel was available after hours, providing real time guidance and expertise. The multidisciplinary nature of this group helped ensure that differential diagnoses overlapping with COVID-19 would be considered as part of a holistic treatment approach, such as E-cigarette or Vaping product use-associated Lung Injury (EVALI) 34 or ARDS. This study is limited by its retrospective nature. It is possible that certain comorbidities thus may have been omitted if not appropriately documented, especially for patients who were new to our system because of the COVID-19 epidemic did not have pre-existing documentation in the EHR. The geography of our patient referral base also means that our description and findings may not translate to other populations throughout the United States with different comorbidities and resources at their disposal. Critically, no location in our system was challenged with an overwhelming surge on the level of New York City during this timeframe. Another limitation to the generalizability of this study is that our enterprise is a consortium comprising of multiple tertiary referral centers. Other health care organizations may not have the bandwidth for extending tertiary care expertise and sharing logistical and planning support across states. Multidisciplinary team-based consensus-driven treatment approaches to COVID-19, complemented with aggressive diagnostic capabilities and outpatient monitoring are associated with low rates of hospitalization and mortality. These best practices learned over time could serve as a template for an effective continuing response to the pandemic. Petrilli J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f Mayo Clinic Strategies for COVID-19: Introduction Diagnostic Stewardship: An Essential Element in a Rapidly Evolving COVID-19 Pandemic Anticoagulation in COVID-19: A Systematic Review, Meta-Analysis and Rapid Guidance From The Mayo Clinic Research Response to SARS-CoV-2/COVID-19 Telemedicine Consultations and Follow-up of Patients With COVID-19 Drive-Through Testing Centers of Disease Control and Prevention. National Healthcare Safety Network (NHSN) Patient Safety Component Manual Remdesivir for the Treatment of Covid-19 -Preliminary Report A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data ICU data mart: a non-iT approach. A team of clinicians, researchers and informatics personnel at the Mayo Clinic have taken a homegrown approach to building an ICU data mart The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients Association of Body mass index (BMI) with Critical COVID-19 and in-hospital Mortality: a dose-response meta-analysis The effect of smoking on COVID-19 severity: A systematic review and meta-analysis Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals We would also like to thank all the healthcare providers, researchers, patients and families who have made these outcomes possible. J o u r n a l P r e -p r o o f